Quantcast

Latest Non-Hodgkin lymphoma Stories

2011-08-19 16:10:00

WHITE PLAINS, N.Y., Aug. 19, 2011 /PRNewswire/ -- Today the Food and Drug Administration (FDA) approved Seattle Genetics' Adcetris to treat two types of rare blood cancers - Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL). (Logo: http://photos.prnewswire.com/prnh/20110215/NY48642LOGO ) The drug is approved for Hodgkin lymphoma patients after failure of a stem cell transplant or two chemotherapy treatments and for ALCL patients after failure of at least one multi-agent...

2011-08-19 13:52:00

SILVER SPRING, Md., Aug. 19, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Adcetris (brentuximab vedotin) to treat Hodgkin lymphoma (HL) and a rare lymphoma known as systemic anaplastic large cell lymphoma (ALCL). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Lymphomas are cancers of the lymphatic system. Adcetris is an antibody-drug conjugate that combines an antibody and drug, allowing the antibody to direct the drug to a target on...

2011-07-25 11:52:09

(Ivanhoe Newswire) "“ Hodgkin's lymphoma is one of the most treatable cancers, with more than 90 percent of patients surviving after a combination of radiation and chemotherapy. New research has found two tiny genetic variations that can predict which patients with Hodgkin's lymphoma are most likely to develop radiation-induced second cancers years after treatment. Knowing in advance who is at risk could help physicians tailor treatment to reduce the risks for patients who are most...

2011-07-19 16:16:51

Study finds novel interaction between 2 proteins that regulate cell growth Researchers at the University of Maryland School of Medicine have discovered a novel interaction between two proteins involved in regulating cell growth that could provide possible new drug targets for treating diffuse large B-cell lymphoma, the most common type of non-Hodgkin's lymphoma. In a study published online in Nature Communications, the scientists report that they have found a complex molecular and functional...

2011-06-09 13:28:23

Researchers from the University of Sheffield have discovered valuable insight into how people develop B-cell lymphoma, one of the most common cancers in the UK. The team, from the University's Institute for Cancer Studies and funded by Leukaemia and Lymphoma Research, Biotechnology and Biological Sciences Research Council (BBSRC) and Yorkshire Cancer Research, found that a mechanism different to that previously thought to be the cause of lymphoma may be responsible for the development of the...

2011-04-06 22:34:40

Researchers at North Carolina State University are narrowing the search for genes involved in non-Hodgkin lymphoma "“ by turning dogs into humans. Humans and dogs don't just share companionship and living space, they also share a similar genetic makeup. Additionally, they share the same types of cancer, including lymphoma. Dr. Matthew Breen, professor of genomics at NC State, uses canines as a genetic model for studying lymphoma because purebred dogs of the same breed have less genetic...

2011-02-16 00:00:00

SAN DIEGO, Feb. 16, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the first patient received subcutaneous (SC) MabThera (rituximab), an anticancer biologic, in a Phase 3 registration trial using Enhanze((TM) technology (rHuPH20, recombinant human hyaluronidase). This represents the second Roche cancer medicine, in addition to Herceptin® SC (trastuzumab), to enter a Phase 3 registration study as...

2010-12-07 07:15:00

ORLANDO, Fla. and SUNNYVALE, Calif., Dec. 7, 2010 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced results from the Phase IA study of its novel orally administered Bruton's tyrosine kinase (Btk) inhibitor, PCI-32765, in patients with relapsed or refractory B cell malignancies. The abstract titled "The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity in Patients with Relapsed/Refractory B-Cell Malignancies: Results from a Phase I study"...


Word of the Day
ween
  • To think; to imagine; to fancy.
  • To be of opinion; have the notion; think; imagine; suppose.
The word 'ween' comes from Middle English wene, from Old English wēn, wēna ("hope, weening, expectation"), from Proto-Germanic *wēniz, *wēnōn (“hope, expectation”), from Proto-Indo-European *wen- (“to strive, love, want, reach, win”).
Related